Core Insights - NeoGenomics reported quarterly earnings of $0.03 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, but down from $0.05 per share a year ago, resulting in an earnings surprise of +50.00% [1] - The company generated revenues of $187.8 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 2.27% and increasing from $167.82 million year-over-year [2] - NeoGenomics shares have declined approximately 38.4% year-to-date, contrasting with the S&P 500's gain of 16.9% [3] Earnings Outlook - The future performance of NeoGenomics stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is $0.04 on revenues of $189.51 million, and for the current fiscal year, it is $0.09 on revenues of $722.29 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which NeoGenomics belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - The correlation between near-term stock movements and earnings estimate revisions suggests that tracking these revisions can provide insights into stock performance [5]

Group 1 - NeoGenomics reported break-even quarterly earnings per share, surprising the market as the consensus estimate was a loss of $0.02, marking a 100% earnings surprise [1] - The company posted revenues of $168.04 million for the quarter ended March 2025, which was 1.66% below the Zacks Consensus Estimate, but an increase from $156.24 million year-over-year [2] - Over the last four quarters, NeoGenomics has surpassed consensus EPS estimates four times and topped revenue estimates twice [2] Group 2 - NeoGenomics shares have declined approximately 39.5% since the beginning of the year, contrasting with the S&P 500's decline of 6% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the next quarter is $0.04 on revenues of $183.07 million, and for the current fiscal year, it is $0.16 on revenues of $738.2 million [7] Group 3 - The Medical - Biomedical and Genetics industry, to which NeoGenomics belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact NeoGenomics' stock performance [5][6]